Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively

GlobeNewsWire • 12 hours ago

MoneyShow's Best Investment Ideas For 2026: Part 2

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 2 of this series includes Axsome Therapeutics, Berkshire Hathaway, Blackstone, Cal-Maine Foods, and Cassiar Gold Corp., among others.

Seeking Alpha • 2 hours ago

HALO or AXSM: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Axsome Therapeutics (AXSM). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jan 9, 2026

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.

MarketBeat • Jan 8, 2026

2 Healthcare Stocks to Buy for 2026 and Beyond

Axsome Therapeutics and Exelixis are generating solid revenue with their current lineups. Both have promising late-stage candidates that should allow them to expand their portfolios.

The Motley Fool • Jan 8, 2026

Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Jan 2, 2026

AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation

Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.

Zacks Investment Research • Jan 2, 2026

Why Axsome Therapeutics Stock Rocketed Higher to End 2025

Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD).

The Motley Fool • Dec 31, 2025

Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug

Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.

Investors Business Daily • Dec 31, 2025

Pharma Stock Soars to Record Highs on FDA Buzz

Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug.

Schaeffers Research • Dec 31, 2025